Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C

A study on how  generic competition can rapidly lower the prices of drugs with high hepatitis C cure rates, like sofosbuvir and daclatasvir and help achieve global treatment scale-up, 12th January, 2016

Click here for more details.

/ News

Share the Post

Related Posts

Read More
Story from Ajitshwor Wangkheirakpam, Manipur, India
Asia-Pacific Aids Groups Express Deep Dismay At Conclusion Of Secretly Negotiated Trans-Pacific Partnership Agreement That Threatens Future Access To Affordable Generic Medicines And Sustainable Development Goals
Patient Groups and CSOs in Asia written a letter to Indian Government to Request Waiver on Local Clinical Trial for The Coming Generic DAAs
Pricing and availability of generic Indian daclatasvir as on 7 March 2016
APN+ joins MTAAG in congratulating Malaysia on sofosbuvir compulsory license
Part 2: How is hepatitis C treated?
New WHO guideline on care and treatment of chronic hepatitis C
Read More
Story from Ayu Oktariani, Bandung, Indonesia